IC 43

Drug Profile

IC 43

Alternative Names: IC-43; OprF-OprI vaccine - Valneva; PE-001; PE-002; Pseudomonas aeruginosa vaccine - Valneva; VLA 43

Latest Information Update: 20 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Novartis
  • Developer Valneva
  • Class Antibacterials; Pseudomonas vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Pseudomonal infections

Most Recent Events

  • 31 Aug 2016 Discontinued - Phase-II/III for Pseudomonal infections (Prevention) in Czech Republic, Spain, Germany, Belgium, Hungary and Austria (IM) because phase II/III trial results did not confirm a positive vaccine effect
  • 21 Mar 2016 Valneva plans a phase III trial for Pseudomonal infections
  • 01 Dec 2015 Valneva completes a phase II/III trial in Pseudomonal infections in Austria, Belgium, Czech Republic, Germany, Hungary and Spain (IM) (NCT01563263)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top